Lineage Cell Therapeutics Inc. — Director's Dealing 2021

May 9, 2021

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Date of Event Requiring Statement (MM/DD/YYYY)	3. Issuer Name and Ticker or Trading Symbol
Jayasuriya Anula	5/4/2021		Lineage Cell Therapeutics, Inc. [LCTX]
(Last) (First) (Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
C/O LINEAGE CELL	X Director _____ 10% Owner
THERAPEUTICS, INC., 2173		_ Officer (give title below) ___ Other (specify below)
SALK AVENUE, SUITE 200
(Street)	5. If Amendment, Date			6. Individual or Joint/Group Filing(Check Applicable Line)
CARLSBAD, CA 92008	Original Filed(MM/DD/YYYY)		X Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip)
	Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned		3. Ownership Form: Direct	4. Nature of Indirect Beneficial Ownership (Instr. 5)
	(Instr. 4)		(D) or Indirect

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivate Security (Instr. 4) 2. Date Exercisable and Expiration Date (MM/DD/YYYY) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative 5. Ownership Form ofDerivative Security: 6. Nature of Indirect Beneficial Ownership (Instr. 5)

(I) (Instr. 5)

Security Direct (D) or Indirect (I) (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% OwnerOfficerOther
Jayasuriya Anula C/O LINEAGE CELL THERAPEUTICS, INC. 2173 SALK AVENUE, SUITE 200 CARLSBAD, CA 92008	X

Signatures

\\Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Brian Culley, the Chief Executive Officer of Lineage Cell Therapeutics, Inc. (the "Company"), Daniel W. Collins, the Associate General Counsel, Intellectual Property of the Company, Alexandra Hernandez, the Principal Accounting Officer of the Company, and Grant Harbert, the Director, Planning and Reporting of the Company, signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (3) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, Forms 3, 4 and 5 in accordance with

• (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, forms and authentication documents for EDGAR Filing Access;
• (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such forms and authentication documents;
• Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
• (4) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
• (5) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the approve in such attorney-in-fact's discretion.

undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date set forth below.

Date: April 30, 2021 /s/ Anula Jayasuriya

Anula Jayasuriya